| pubmed-article:14996706 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14996706 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:14996706 | lifeskim:mentions | umls-concept:C0079731 | lld:lifeskim |
| pubmed-article:14996706 | lifeskim:mentions | umls-concept:C0162768 | lld:lifeskim |
| pubmed-article:14996706 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:14996706 | lifeskim:mentions | umls-concept:C0085101 | lld:lifeskim |
| pubmed-article:14996706 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:14996706 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:14996706 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:14996706 | pubmed:dateCreated | 2004-6-21 | lld:pubmed |
| pubmed-article:14996706 | pubmed:abstractText | Pretargeted radioimmunotherapy (PRIT) has the potential to increase the dose of radionuclide delivered to tumors while limiting radiation to normal tissues. The purpose of this phase 1 trial is to assess safety of this multistep approach using a novel tetrameric single-chain anti-CD20-streptavidin fusion protein (B9E9FP) as the targeting moiety in patients with B-cell non-Hodgkin lymphoma (NHL), and to characterize its pharmacokinetics and immunogenicity. All patients received B9E9FP (160 mg/m(2) or 320 mg/m(2)); either 48 or 72 hours later, a synthetic clearing agent (sCA) was administered (45 mg/m(2)) to remove circulating unbound B9E9FP. (90)Yttrium ((90)Y; 15 mCi/m(2))/(111)In (5 mCi)-DOTA-biotin was injected 24 hours later. There were 15 patients enrolled in the study. B9E9FP had a mean plasma half-life (T(1/2)) of 25 +/- 6 hours with a reduction in plasma level of more than 95% within 6 hours of sCA administration. (90)Y/(111)In-DOTA-biotin infusion resulted in rapid tumor localization and urinary excretion. The ratio of average tumor to whole-body radiation dose was 49:1. No significant hematologic toxicities were noted in 12 patients. There were 2 patients who had hematologic toxicity related to progressive disease. There were 2 complete remissions (90 and 325 days) and one partial response (297 days). B9E9FP performs well as the targeting component of PRIT with encouraging dosimetry, safety, and efficacy. A dose escalation trial of (90)Y-DOTA-biotin in this format is warranted. | lld:pubmed |
| pubmed-article:14996706 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14996706 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14996706 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14996706 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14996706 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14996706 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:14996706 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14996706 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14996706 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14996706 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:14996706 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:SahuR PRP | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:KnoxSusan JSJ | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:VoseJulie MJM | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:MeredithRuby... | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:LoBuglioAlber... | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:GorisMichael... | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:WeidenPaul... | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:AxworthyDon... | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:PicozziVincen... | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:ForeroAndresA | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:HankinsJordan... | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:BreitzHazel... | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:SimsRobert... | lld:pubmed |
| pubmed-article:14996706 | pubmed:author | pubmed-author:GhalieRichard... | lld:pubmed |
| pubmed-article:14996706 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14996706 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:14996706 | pubmed:volume | 104 | lld:pubmed |
| pubmed-article:14996706 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14996706 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14996706 | pubmed:pagination | 227-36 | lld:pubmed |
| pubmed-article:14996706 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:meshHeading | pubmed-meshheading:14996706... | lld:pubmed |
| pubmed-article:14996706 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:14996706 | pubmed:articleTitle | Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. | lld:pubmed |
| pubmed-article:14996706 | pubmed:affiliation | University of Alabama at Birmingham Comprehensive Cancer Center, 35294-3300, USA. andres.forero@ccc.uab.edu | lld:pubmed |
| pubmed-article:14996706 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14996706 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:14996706 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:14996706 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:14996706 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:14996706 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14996706 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14996706 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14996706 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14996706 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14996706 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14996706 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14996706 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14996706 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14996706 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14996706 | lld:pubmed |
